UMIN ID: UMIN000053952
Registered date:01/06/2024
Persistence and safety of Mirikizumab in patients with active ulcerative colitis
Basic Information
| Recruitment status | Recruiting |
|---|---|
| Health condition(s) or Problem(s) studied | ulcerative colitis |
| Date of first enrollment | 2024/05/10 |
| Target sample size | 50 |
| Countries of recruitment | Japan |
| Study type | Observational |
| Intervention(s) |
Outcome(s)
| Primary Outcome | Persistence of mirikizumab at week 40 |
|---|---|
| Secondary Outcome |
Key inclusion & exclusion criteria
| Age minimum | 18years-old |
|---|---|
| Age maximum | Not applicable |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | Patients without informed consent Patients inappropriate for this study Patients experienced mirikizumab treatment Patients performed colectomy Patinet who are pregnant or breastfeeding Patients undergoing cancer treatment |
Related Information
| Primary Sponsor | Saitama Medical Center, Saitama Medical University |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Saitama Medical Center, Saitama Medical University |
| Secondary ID(s) |
Contact
| public contact | |
| Name | SHINGO KATO |
| Address | 1981, Kamoda, Kawagoe City, Saitama, Japan Japan 350-8550 |
| Telephone | 049-228-3654 |
| skato@saitama-med.ac.jp | |
| Affiliation | Saitama Medical Center, Saitama Medical University Department of Gastroenterology and Hepatology |
| scientific contact | |
| Name | SHINGO KATO |
| Address | 1981, Kamoda, Kawagoe City, Saitama, Japan Japan |
| Telephone | 049-228-3564 |
| skato@saitama-med.ac.jp | |
| Affiliation | Saitama Medical Center, Saitama Medical University Department of Gastroenterology and Hepatology |